MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2025-09-30, FENC had $3,242K increase in cash & cash equivalents over the period.

Cash Flow Overview

Change in Cash
$3,242K

Unit: Thousand (K) dollars (except for numbers of shares and EPS)
Cash Flow
2025-09-30
2025-06-30
Net (loss)/income
-637 -4,317
Inventory reserve
-517 -
Allowance for credit losses
-1,155 1,222
Amortization of debt discount
12 26
Loss on securities
0 2
Amortization of norgine asset
26 51
Stock-based compensation - employees
2,219 2,292
Accounts receivable
3,440 5,542
Prepaid expenses
-3,340 1,659
Inventory
276 1,141
Other assets
-520 435
Accounts payable
-75 2,700
Accrued liabilities
1,476 -1,203
Net cash (used in) / provided by operating activities
1,493 -8,004
Issuance of shares, options exercise
1,799 186
Cash paid for taxes on restricted share release
50 111
Net cash provided by / (used in) financing activities
1,749 75
(decrease) / increase in cash and cash equivalents
3,242 -7,929
Cash and cash equivalents at beginning of period
26,634 -
Cash and cash equivalents at end of period
21,947 -
Unit: Thousand (K) dollars

Time Plot

Show the time plot by selecting a row from the table.

FENNEC PHARMACEUTICALS INC. (FENC)

FENNEC PHARMACEUTICALS INC. (FENC)